TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32009091
Drug: Lenalidomide plus
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide plus dexamethasone (15 mg in cycle 1, 25 mg in cycles 2-6, dexamethasone 20 mg once a week)
Study: 33453514
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (ET) 3 times/week for 12 weeks
Study: 34335819
Drug: Garlic tablets
DrugBank: Garlic (DB10532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic tablets (400 mg)
Study: 34768722
Drug: Novel influenza
Normalized name: Novel influenza-H1N1-09
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel influenza vaccine with continuous monitoring using a wearable sensor.
Study: 33535811
Drug: Experimental COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental COVID-19 vaccine
Study: 33535811
Drug: Active comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator vaccine
Study: 34210242
Drug: Co-supplementation group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-supplementation group (n = 27): 50000 IU vitamin D soft gel weekly + 250 mg magnesium tablet daily
Study: 34210242
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D group (n = 27): 50000 IU vitamin D soft gel weekly + magnesium placebo daily
Study: 34210242
Drug: Magnesium group
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium group (n = 27): vitamin D placebo weekly + 250 mg magnesium tablet daily
Study: 34210242
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 27): vitamin D placebo weekly + magnesium placebo daily
Study: 37949090
Drug: Moxidectin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxidectin (8 mg)
Study: 33657442
Drug: Alcoholic drink
Normalized name: Alcoholic drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcoholic drink (0.6 g/kg)
Study: 33657442
Drug: Alcoholic drink
Normalized name: Alcoholic drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcoholic drink (0.3 g/kg)
Study: 33130217
Drug: pm‐Pac (230
Approvals — FDA: no, EMA: no, PMDA: no
Description: pm‐Pac (230 mg/m2) plus cisplatin (70 mg/m2)
Study: 33130217
Drug: sb‐Pac (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: sb‐Pac (175 mg/m2) plus cisplatin (70 mg/m2)
Study: 32318809
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg daily for 7 days
Study: 34678981
Drug: Sevelamer (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevelamer (2400 mg daily)
Study: 34678981
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (1500 mg daily)
Study: 32821251
Drug: Recollection-based occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recollection-based occupational therapy program (24 sessions, 5 times per week for 1 hour each)
Study: 34131002
Drug: Prexasertib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prexasertib at 70 mg/m2 i.v. with olaparib at 100 mg by mouth twice daily
Study: 32763538
Drug: Repetitive transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive transcranial magnetic stimulation (rTMS), 20 treatments over four weeks
Study: 36459264
Drug: CHARISMA intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHARISMA intervention to increase women's agency to use oral pre‐exposure prophylaxis (PrEP) safely and consistently.
Study: 33892086
Drug: Effective Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective Dose 50 (ED50) method for depression
Study: 35609409
Drug: Standard pemetrexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pemetrexed maintenance therapy
Study: 34006055
Drug: 3% Hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% Hypertonic saline (HS) solution
Study: 35334570
Drug: L-alanyl L-glutamine
Normalized name: L-Alanyl-L-glutamine
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-alanyl L-glutamine dipeptide
Study: 33831213
Drug: Exenatide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (2 mg, subcutaneously, once-weekly)
Study: 33831213
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT, 21 mg)
Study: 34867725
Drug: Passive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive treatment (historical control)
Study: 34867725
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (historical control)
Study: 34867725
Drug: Prism Adaptation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prism Adaptation treatment with fewer therapy sessions (historical control)
Study: 34758057
Drug: High flow:
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow: 70 l · min‐1, continuous jaw thrust
Study: 34758057
Drug: Medium flow:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium flow: 10 l · min‐1, continuous jaw thrust
Study: 34758057
Drug: Low flow:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flow: 2 l · min‐1, continuous jaw thrust
Study: 34758057
Drug: Minimal flow:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal flow: 0.25 l · min‐1, endotracheal tube
Study: 34362525
Drug: Non ABO‐HDN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non ABO‐HDN direct antibody test
Study: 33932000
Drug: Fluoxetine hydrochloride
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine hydrochloride capsule 20 mg once a day
Study: 35603590
Drug: Fibre/water (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre/water (2 l/day)
Study: 33616613
Drug: Telephone Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone Cognitive Behavioral Therapy for Insomnia (CBT-I)
Study: 32876697
Drug: Fixed-dose hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fixed-dose hydrocortisone (50 mg or 100 mg every 6 hours)
Study: 32876697
Drug: Shock-dependent hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Shock-dependent hydrocortisone (50 mg every 6 hours when shock was clinically evident)
Study: 36009980
Drug: Colistin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin combined with sulbactam at 12 g/day
Study: 36009980
Drug: Colistin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colistin combined with sulbactam at 9 g/day
Study: 32617651
Drug: Subchondral cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subchondral cell therapy (20 mL of bone marrow concentrate with 5727 MSCs/mL)
Study: 32617651
Drug: Intra-articular cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular cell therapy (20 mL of bone marrow concentrate with 5727 MSCs/mL)
Study: 32202692
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered in the same dosing schedule as oxytocin)
Study: 35631293
Drug: CBD (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (30 mg)
Study: 35631293
Drug: CBD (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (30 mg) with food
Study: 33931829
Drug: Peloid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peloid therapy + home exercise program
Study: 35000098
Drug: Single-dose paltusotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose paltusotine 1.25 to 20 mg
Study: 35000098
Drug: Multiple-dose paltusotine
Normalized name: Paltusotine
DrugBank: Paltusotine (DB16277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose paltusotine 5 to 30 mg administered once daily for 10 days
Study: 34189636
Drug: Trabectedin 1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin 1.1 mg/m2 plus pegylated liposomal doxorubicin (PLD) 30 mg/m2, administered intravenously every 21 days until disease progression or unacceptable toxicity.
Study: 32212418
Drug: Oral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral moxifloxacin 400 mg (positive control)
Study: 35289500
Drug: Olmesartan medoxomil/amlodipine
Normalized name: olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide 40 mg-5 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan medoxomil/amlodipine besylate tablet (20 mg/5 mg) under fasting conditions
Study: 35289500
Drug: Olmesartan medoxomil/amlodipine
Normalized name: olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide 40 mg-5 mg-25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan medoxomil/amlodipine besylate tablet (20 mg/5 mg) under fed conditions
Study: 32165403
Drug: FENO guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FENO guided treatment (not treated with LTRA)
Study: 32165403
Drug: FENO guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FENO guided treatment (non-obese children)
Study: 35652746
Drug: Centanafadine 200
Normalized name: Centanafadine
DrugBank: Centanafadine (DB14841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centanafadine 200 mg/d
Study: 35652746
Drug: Centanafadine 400
Normalized name: Centanafadine
DrugBank: Centanafadine (DB14841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centanafadine 400 mg/d
Study: 36272502
Drug: DON group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: DON group (10 mg DON/kg of feed)
Study: 32762663
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-Acetylcysteine (NAC) at a fixed dose of 2.7 g/day (900 mg three times daily) for 12 weeks
Study: 36321334
Drug: VSD combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: VSD combined with flap transplantation and immunosuppressive agent treatment
Study: 36321334
Drug: Normal dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dressing change combined with hormone and cyclosporine
Study: 33763794
Drug: Pilocarpine administration
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine administration
Study: 33039671
Drug: Initial care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial care for early fasting hyperglycaemia (n = 137, FPG ≥ 5.5 mmol/L)
Study: 33992615
Drug: Lipiflow treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipiflow treatment 3 weeks before cataract surgery
Study: 33992615
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Lipiflow treatment)
Study: 36110574
Drug: Anti-PD-1 immunotherapy
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 immunotherapy (sintilimab) combined with gemcitabine chemotherapy
Study: 34147766
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus Enhanced Medication Management (SERT + EMM)
Study: 34147766
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure plus Sertraline (PE + SERT)
Study: 35610575
Drug: Water (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (5 mL/kg)
Study: 35610575
Drug: High-carbohydrate drink
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-carbohydrate drink (5 mL/kg)
Study: 36048382
Drug: Aqueous extract
Normalized name: green tea aqueous extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous extract of seed of broccoli, dosage and duration not available
Study: 33140122
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of inorganic nitrate (NO3−); specific dosage and duration not mentioned.
Study: 35932386
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A (fed condition)
Study: 35932386
Drug: Formulation A
Normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A (multiple doses)
Study: 33113440
Drug: Dietary alpha-lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary alpha-lipoic acid (ALA) supplementation (300 mg/kg)
Study: 37858247
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) supplementation
Study: 35244070
Drug: Nerve block
Normalized name: Nerve Block Tray 22g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve block therapy (NBT) + acupotomy
Study: 35244070
Drug: Nerve block
Normalized name: Nerve Block Tray 22g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve block therapy (NBT)
Study: 33778937
Drug: Intraperitoneal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal glucose injection
Study: 33778937
Drug: Glutamate antagonist
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate antagonist (CNQX + refeeding)
Study: 33778937
Drug: Glutamate antagonist
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate antagonist (CNQX + glucose)
Study: 33789971
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) - two sessions
Study: 34392573
Drug: Hydrogen peroxide
Normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrogen peroxide topical solution 35% (H2 O2)
Study: 35549757
Drug: Qingpeng ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingpeng ointment applied topically at involved joints twice a day for consecutive 7 days
Study: 35549757
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment applied topically at involved joints twice a day for consecutive 7 days
Study: 32098501
Drug: Exenatide 2
Normalized name: exenatide 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 2 mg
Study: 32098501
Drug: Any glucose-lowering
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any glucose-lowering medication
Study: 32098501
Drug: All glucose-lowering
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: All glucose-lowering medications
Study: 32098501
Drug: Cardioprotective glucose-lowering
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioprotective glucose-lowering agents
Study: 36096147
Drug: RTS,S/AS01E malaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01E malaria vaccine
Study: 33811730
Drug: Permanent polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permanent polymer zotarolimus-eluting stent (PP-ZES) in insulin-treated diabetics
Study: 33811730
Drug: Polymer-free amphilimus-eluting
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymer-free amphilimus-eluting stent (PF-AES) in insulin-treated diabetics
Study: 35123510
Drug: Macitentan treatment
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Macitentan treatment
Study: 35543102
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg twice weekly for 16 weeks)
Study: 33535474
Drug: BRAINballs program
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRAINballs program (conducted twice a week)
Study: 33218845
Drug: Biostimulant formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biostimulant formulation 2 at a dosage of 0.25 kg ha-1
Study: 33218845
Drug: Biostimulant formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biostimulant formulations (F1, F2, F3) at dosages of 0.25, 0.50, and 1.0 kg ha-1
Study: 39102111
Drug: Conventional diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional diet (0.8-1.0 g/kg/day of protein)
Study: 35608270
Drug: 4 mg/ml
Normalized name: valine 4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/ml dilution of vancomycin
Study: 35608270
Drug: 20 mg/ml
Normalized name: urea 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/ml dilution of vancomycin
Study: 33317565
Drug: Peanut protein
Normalized name: peanut protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut protein (PP) supplement (75 total g powder providing 30 g protein, >9.2 g essential amino acids, 315 kcal; n=20)
Study: 33317565
Drug: Control (CTL;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (CTL; no supplement; n=19)
Study: 33317565
Drug: Peanut protein
Normalized name: peanut protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut protein (PP) supplement
Study: 33317565
Drug: Peanut protein
Normalized name: peanut protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut protein (PP) supplement (10-week group)
Study: 33465382
Drug: Abdominal massage
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal massage using 'I LOV U' method along with lifestyle education, 15 min, twice daily for 10 days.
Study: 34021915
Drug: IV dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV dexamethasone (2 mL, 8 mg)
Study: 34021915
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mL IV solution)
Study: 32081056
Drug: Herbal combination
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal combination
Study: 35944104
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia using propofol (Group T)
Study: 35944104
Drug: Inhalation general
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation general anesthesia using sevoflurane (Group I)
Study: 32745732
Drug: Smartphone application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone application for medication adherence (6 months)
Study: 33276251
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol MDI HFA (250 μg/50 μg, twice daily)
Study: 33276251
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol DPI (500 μg/50 μg, twice daily)
Study: 35544095
Drug: Dihydroartemisinin-piperaquine plus
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine plus tafenoquine 0.42 mg/kg
Study: 35544095
Drug: Dihydroartemisinin-piperaquine plus
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine plus tafenoquine 0.83 mg/kg
Study: 35544095
Drug: Dihydroartemisinin-piperaquine plus
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine plus tafenoquine 1.66 mg/kg
Study: 35136296
Drug: Targeted fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted fluid therapy (Group-T)
Study: 35136296
Drug: Standard fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fluid therapy (Group-S)
Study: 32409830
Drug: Preoperative chemoradiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy
Study: 32409830
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus adjuvant chemotherapy (standard treatment)
Study: 32411431
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab injections
Study: 34352146
Drug: MFU‐V combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFU‐V combined with L‐HA injection (combined technique)
Study: 34352146
Drug: MFU‐V monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFU‐V monotherapy (single technique)
Study: 32542370
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (200 mg Venofer® in 100 ml saline on days 1, 3, and 5)
Study: 33208325
Drug: Zinc biofortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc biofortified wheat flour (target zinc concentration of 40 mg/kg)
Study: 33208325
Drug: Locally procured
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locally procured wheat flour from standard varieties (expected zinc concentration of 20 mg/kg)
Study: 33648568
Drug: Dexamethasone 20
Normalized name: dexamethasone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 20 mg intravenously once daily on days 1-5, followed by 10 mg on days 6-10
Study: 33648568
Drug: Dexamethasone 6
Normalized name: dexamethasone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 6 mg intravenously once daily on days 1-10
Study: 35033182
Drug: Dexamethasone 20
Normalized name: dexamethasone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 20 mg
Study: 35462372
Drug: Desidustat 100
Normalized name: Desidustat
DrugBank: Desidustat (DB16135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desidustat 100 mg oral tablets thrice a week for 24 weeks
Study: 35462372
Drug: Biosimilar darbepoetin
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biosimilar darbepoetin subcutaneous injection 0.75 μg/kg once in 2 weeks for 24 weeks
Study: 33580472
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids treatment for 16 weeks
Study: 36447623
Drug: Immersive Virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immersive Virtual Reality (VR) therapy